Objective: To detail studies investigating the efficacy/safety of semaglutide as a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in the treatment of type 2 diabetes mellitus. Data Sources: A literature search in MEDLINE and ClinicalTrials. gov (January 2013 to May 2018) using the terms semaglutide, SUSTAIN, oral, and PIONEER resulted in 10 published articles and 14 ongoing/unpublished articles. Study Selection and Data Extraction: All English language phase 2 and 3 clinical trials evaluating efficacy/safety of semaglutide were included. Data Synthesis: In 9 phase 3, multicenter SUSTAIN trials, the efficacy and safety of semaglutide have been compared with placebo and other pharmacologic therapy for diabetes (PTD). In these trials, semaglutide resulted in lower hemoglobin A 
Introduction
The 2017 National Diabetes Statistics Report indicates that 30.3 million people in the United States have diabetes with an estimated incidence of 1.5 million cases. Of the 30.3 million people affected, 90% to 95% of these cases are type 2 diabetes mellitus (T2DM).
1 T2DM is a complex disease characterized by progressive loss of pancreatic β-cell insulin secretion and insulin resistance leading to variable blood glucose levels. 2 The glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug class is indicated for the treatment of T2DM. Medications in this group include the following: Trulicity (dulaglutide), Byetta (exenatide), Bydureon, Bydureon BCise (exenatide extended release [ER] ), Victoza (liraglutide), and Adlyxin (lixisenatide). These are subcutaneous injectable agents that activate the GLP-1 receptors leading to increased glucosedependent insulin secretion, decreased glucose-dependent glucagon secretion, slowed gastric emptying, and increased satiety.
2 GLP-1 RAs decrease hemoglobin A 1c (HbA 1c ) and provide benefits such as weight loss, low risk of hypoglycemia, and some cardiovascular (CV) protection as compared with other agents. 3 With the benefits beyond glucose control capabilities, GLP-1 RAs offer more acceptable clinical application profiles for providers managing patients with T2DM. Novo Nordisk, Inc, recently developed a new GLP-1 RA, Ozempic (semaglutide), which was approved by the US Food and Drug Administration on December 5, 2017. This article reviews clinical trials assessing semaglutide and offers clinical details to further understand its role as a glucose-lowering medication for patients with T2DM.
Data Selection
A MEDLINE search for primary literature published from January 1, 2013, to May 31, 2018, was performed using search terms semaglutide and SUSTAIN and semaglutide and oral. ClinicalTrials.gov website was also reviewed with terms semaglutide and SUSTAIN and semaglutide and PIONEER. A total of 10 published articles and 14 ongoing/ unpublished articles were identified.
Pharmacology, Pharmacodynamics, and Pharmacokinetics
Semaglutide is a GLP-1 RA of human GLP-1 with 94% sequence homology. Semaglutide contains a peptide backbone with the addition of a hydrophilic spacer and C18 fatty di-acid at position 26 lysine and modifications at positions 8 and 34. These modifications result in albumin binding and protection from the enzyme dipeptidyl peptidase-4 degradation. In a glucose-dependent manner, inhibition of glucagon (fasting/postprandial) secretion, enhanced stimulation of insulin (first-/second-phase release), and slight delay in postprandial gastric emptying are responsible for the glucose lowering effects. 5 Following a carbohydrate-rich breakfast, semaglutide has been shown to reduce 1-hour gastric emptying by 27% as compared with placebo. 6 Concentrations of subcutaneous semaglutide peak within 3 days and steady state is achieved by week 5 of once-weekly administration. The plasma concentration of subcutaneous semaglutide exhibits dose-proportional increases with once-weekly administration; however, increased body weight has shown to decrease exposure. The elimination half-life (t 1/2 ) is 1 week, and the drug stays in circulation for approximately 5 weeks after the last dose. 7 The majority of excretion is through urine and feces, with only 3% of dose unchanged in the urine. Semaglutide is more than 99% bound to plasma albumin, which contributes to the prolonged exposure.
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Dosage Recommendations
The dosage form of semaglutide is a 2 mg/1.5 mL injection available in 2 single-use prefilled pen formulations: a pen that delivers 0.25 mg or 0.5 mg per injection and a pen that delivers 1.0 mg per injection. Semaglutide should be administered subcutaneously once weekly without regard to meals. Semaglutide should be commenced at 0.25 mg weekly subcutaneously, then increased to 0.5 mg after 4 weeks. If further glucose control is needed after 4 weeks of the 0.5 mg dose, the maximum dose of 1.0 mg may be achieved. Semaglutide does not require dose adjustments for renal or hepatic impairment.
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Clinical Studies Evaluating Efficacy
The efficacy of once-weekly semaglutide 0.5 mg and 1.0 mg has been compared with placebo, oral pharmacologic therapy for diabetes (PTD), GLP-1 RAs, and basal insulin in 9 completed and 4 ongoing phase 3 multicenter studies: the SUSTAIN program. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] SUSTAIN trials 8, 9, 10, and CHINA-MRCT are ongoing and will be excluded from further review. [15] [16] [17] [18] In completed studies, both doses of semaglutide significantly reduced HbA 1c and body weight as compared with the control treatment ( Table 1) . [8] [9] [10] [11] [12] [13] [14] 19, 20 SUSTAIN studies 2, 3, 4, 5, and 7 showed superiority at improving glycemic control and reducing body weight as compared with sitagliptin, exenatide ER 2.0 mg, insulin glargine U100, placebo as add-on therapy to basal insulin alone or in combination with metformin, and dulaglutide, respectively.
9-12,14 SUSTAIN 1 was a 7-month study conducted in adults with T2DM using diet and exercise. At 7 months, the HbA 1c and body weight were significantly lowered by 0.5 mg and 1.0 mg semaglutide as compared with diet and exercise alone. Both doses of semaglutide had similar HbA 1c reductions.
8 SUSTAIN 2 used sitagliptin as a comparator and included adults with T2DM using oral PTD (metformin, pioglitazone, rosiglitazone, or combo of metformin and pioglitazone, or metformin and rosiglitazone). At 1 year, the mean HbA 1c and body weight were significantly reduced by both doses of semaglutide as compared with sitagliptin.
9 SUSTAIN 3 compared semaglutide 1.0 mg with exenatide ER 2.0 mg and included patients with T2DM that were on 1 or 2 oral PTD (metformin, thiazolidinedione, and/ or sulfonylurea [SFU]). Semaglutide significantly reduced both the mean HbA 1c and body weight after 1 year. 10 In SUSTAIN 4, semaglutide or insulin glargine U100 were added on to pretrial treatment of metformin alone or in combination with a SFU in patients with T2DM. Insulin glargine U100 was initiated at 10 units once daily and titrated weekly to a fasting self-measured plasma glucose target of 72 to 99 mg/dL with an average insulin glargine dose of 29.2 units per day at the end of the study. By 7 months, both doses of semaglutide significantly reduced the mean HbA similarly. 12 In SUSTAIN 1, 2, 4, and 5, the 1.0 mg semaglutide dose had a greater reduction in body weight as compared with the 0.5 mg dose. 8, 9, 11, 12 SUSTAIN 6 evaluated CV outcomes for both doses of semaglutide versus placebo and included adults with T2DM and high CV risk with no PTD or ⩽2 oral PTD with or without insulin ( Table 2 ). High CV risk was defined by 2 categories in the study. The first category was defined as age 50 years and older with established CV disease including at least one of the following: prior myocardial infarction; stroke or transient ischemic attack; arterial revascularization; more than 50% stenosis of coronary, carotid, or lower extremities arteries; symptomatic coronary heart disease; asymptomatic cardiac ischemia; New York Heart Association class II to III chronic heart failure; and chronic renal impairment with an estimated glomerular filtration rate <60 mL/min/1.73 m 2 . The second category was defined as age 60 years and older with at least one of the following CV risk factors: microalbuminuria (30-299 mg/g or proteinuria); hypertension with left ventricular hypertrophy; left ventricular systolic or diastolic dysfunction; and ankle/brachial index <0.9. As for glycemic efficacy, both doses significantly lowered mean HbA 1c and body weight as compared with placebo after 2 years; however, the 1.0 mg semaglutide dose lowered body weight further as compared with the 0.5 mg dose (−1.3 kg difference). As for lowering CV risk, patients receiving semaglutide had a significant 26% lower risk of death from CV causes, nonfatal myocardial infarction, or nonfatal stroke as compared with patients taking placebo after 2 years. The study does not report the differences in outcomes of the 2 doses of semaglutide and rather analyzes both doses together. 
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Clinical Trials Evaluating Safety
Across the SUSTAIN studies, similar adverse events were reported for semaglutide with the most common as mild to moderate gastrointestinal adverse events seen throughout the GLP-1 RA class. 8 In particular, nausea is typically present at initiation of semaglutide and diminishes over time.
Semaglutide had a <3% rate of severe or blood glucose confirmed symptomatic hypoglycemic episodes in SUSTAIN studies 1, 2, 7, JP PTD, and JP Mono (Table 3) . 8, 9, 14, 19, 20 SUSTAIN trials 3, 4, 5, and 6 had higher rates of hypoglycemic episodes for semaglutide with SUSTAIN 6 having the highest rate of 23.1% for 0.5 mg semaglutide. [10] [11] [12] [13] In these trials, insulin or insulin secretagogues were used as comparator or background treatments.
The occurrence of acute pancreatitis events was low and reported as ⩽1% throughout the SUSTAIN trials for both doses of semaglutide. The comparator groups in these studies (placebo, sitagliptin, exenatide ER, insulin glargine, dulaglutide) exhibited comparable occurrences of acute pancreatitis events with the highest occurrence of 1.1% for placebo in the SUSTAIN 6 trial. [8] [9] [10] [11] [12] [13] [14] 19, 20 Most of the pancreatitis episodes were classified as mild. The rate of cholelithiasis was ⩽2.5%, and the incidence of malignant neoplasms was ⩽4.9% across the SUSTAIN trials for semaglutide. [8] [9] [10] [11] [12] [13] [14] 19, 20 More malignant neoplasms were reported in the semaglutide groups in SUSTAIN trials 1, 3, 4 (0.5 mg dose only), 5, and 6 (1.0 mg dose only). 8, [10] [11] [12] [13] In SUSTAIN 3, malignant neoplasms occurred at a higher frequency in the semaglutide group versus exenatide ER (2% vs 0.5%) with no pattern of organ distribution. 10 Although SUSTAIN 6 reported a higher rate of malignant neoplasms in the 1.0 mg semaglutide group, the rates were similar among the semaglutide and placebo groups. 13 The incidence of thyroid malignant neoplasms was low in the SUSTAIN trials. SUSTAIN 2 reported 1 case of papillary thyroid cancer in the 1.0 mg semaglutide group.
9 SUSTAIN 6 did not report any medullary thyroid carcinomas in the trial. 13 SUSTAIN JP Mono did not show any thyroid neoplasms or medullary thyroid carcinomas, and SUSTAIN JP PTD did not report medullary thyroid carcinomas either. 19, 20 As for immunogenicity, SUSTAIN studies 1, 2, 3, 6, JP Mono, and JP PTD had subjects that developed antibodies against semaglutide. [8] [9] [10] 13, 19, 20 However, most of the antisemaglutide antibodies did not neutralize semaglutide or endogenous GLP-1 in vitro. SUSTAIN 6 had only 4 patients with antibodies during follow-up (30 patients initially) and only 1 subject in SUSTAIN JP Mono had anti-semaglutide antibodies throughout the trial that resulted in a negative antibody test at follow-up. 13, 20 The decrease in number of subjects with a positive antibody test at follow-up suggests that the antibody formation is transient. SUSTAIN 6 trial found that subjects receiving semaglutide had a significant 36% lower risk of new or worsening nephropathy, but a significant 76% higher risk of retinopathy complications (vitreous hemorrhage, blindness, or circumstances requiring treatment with an intravitreal agent or photocoagulation) as compared with placebo. Although the occurrence of retinopathy complications was low in the semaglutide pooled groups (3%), 66 out of the 79 patients (83.5%) with retinopathy complications had baseline retinopathy (42 out of 50 semaglutide group patients [84.0%] and 24 out of 29 placebo group patients [82.8%]). 13 Retinopathy complications are unique to semaglutide within the GLP-1 RA class and may require additional monitoring. A possible theory for the increased retinopathy complications is the relationship between worsening retinopathy and rapid glucose reductions that have been previously described in insulin-dependent patients. 21, 22 However, this proposed association does not eliminate the possibility of semaglutide having a direct effect on patients' eyes. 2,23 SUSTAIN 6 trial for semaglutide included similar high CV risk patients as the LEADER trial and the CV risk reduction was consistent with liraglutide. 13, 23 The evidence suggests that semaglutide may be an option to lower CV risk in patients with T2DM and ASCVD.
Semaglutide may have a benefit over other GLP-1 RAs with regard to greater weight reduction, use in renal impairment, and potential oral tablet formulation. Semaglutide provides greater weight loss reduction of roughly 4 kg while the other GLP-1 RAs reduce body weight by approximately 1.4 to 2.5 kg. In addition, semaglutide does not require renal dose adjustments unlike exenatide and exenatide ER. 24 Semaglutide also has an oral tablet formulation in phase 3 clinical trials (the PIONEER program), which is unique within the GLP-1 RA class of subcutaneous injections. The phase 3 trial, PIONEER 1, assessed the efficacy and safety of once-daily oral semaglutide in 3, 7, and 14 mg doses as compared with placebo in patients with T2DM using diet and exercise alone. Patients treated with oral semaglutide exhibited greater HbA 27,28 A phase 2 study comparing different oral dosages of semaglutide tablets with subcutaneous semaglutide showed that the 40 mg tablet lowered HbA1c and body weight similarly to 1.0 mg subcutaneous semaglutide; however, the 40 mg tablet at standard dose escalation resulted in more gastrointestinal adverse events.
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Summary
Semaglutide is a recently approved GLP-1 RA with a long duration of action allowing for once-weekly dosing. Semaglutide is administered subcutaneously, but may eventually be available as an oral tablet formulation. The SUSTAIN trial program has shown that semaglutide improves glycemic control and provides weight loss in patients with T2DM, with evidence for CV risk reduction and higher risk of retinopathy complications. More data need to be evaluated to find out the causality of retinopathy noted. However, a risk versus benefit discussion with patients is essential.
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